logo

Sanjiv Agarwala, MD

Sanjiv Agarwala, MD

Oncology Bethlehem, PA

Physician

Office Address

Office Map
  • 801 Ostrum Street
    Bethlehem, PA 18015
    Phone: (484) 526-2140
    Fax: (484) 526-6055

Dr. Agarwala's Clinical Specialties & Interests

  • Oncology: General Oncology

Dr. Agarwala's Education & Medical Training

  • University of Pittsburgh Medical CenterUniversity of Pittsburgh Medical CenterResidency, Internal Medicine
  • University of Pittsburgh Medical CenterUniversity of Pittsburgh Medical CenterFellowship, Hematology/Oncology
  • Seth G.S. Medical CollegeSeth G.S. Medical CollegeMedical School

Dr. Agarwala's Certifications & Licensure

  • PA State Medical LicensePA State Medical License1993 - 2014
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine
  • American Board of Internal MedicineAmerican Board of Internal MedicineHematology
  • American Board of Internal MedicineAmerican Board of Internal MedicineMedical Oncology

Dr. Agarwala's Clinical Trials

Dr. Agarwala's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • Ph1 Stdy Epidermal Grwth FCT REC Tyrosine Kinase INH Combo W/Docetaxel
    Ph1 Stdy Epidermal Grwth FCT REC Tyrosine Kinase INH Combo W/DocetaxelNational Center For Research Resources
    2005 - 2005
  • PH II UCN-01 Metastatic  Melanoma
    PH II UCN-01 Metastatic MelanomaNational Center For Research Resources
    2005 - 2005
  • Ph3, Mc, Ol, Surv/Safety Study Of Head/Neck Carcinoma
    Ph3, Mc, Ol, Surv/Safety Study Of Head/Neck CarcinomaNational Center For Research Resources
    2004 - 2004
  • PHI Dose Escal. Study Eval Safety Of Albuleukin
    PHI Dose Escal. Study Eval Safety Of AlbuleukinNational Center For Research Resources
    2004 - 2004
  • Ph1 Study EGFR Tyrosine Kinase Inhibitor W/ Docetaxel
    Ph1 Study EGFR Tyrosine Kinase Inhibitor W/ DocetaxelNational Center For Research Resources
    2004 - 2004
  • A RAND Study Of Four Weeks High Dose IFN 2B In Melanoma
    A RAND Study Of Four Weeks High Dose IFN 2B In MelanomaNational Center For Research Resources
    2004 - 2004
  • Four Week High Dose Interferon A2B In Stage IIA Melanoma
    Four Week High Dose Interferon A2B In Stage IIA MelanomaNational Center For Research Resources
    2000 - 2002
  • Temozolomide In Treatment Of Metastatic Melanoma W/ Brain Metastases
    Temozolomide In Treatment Of Metastatic Melanoma W/ Brain MetastasesNational Center For Research Resources
    1999 - 2000
  • Recombinant Keratinocyte Growth Factor For Head &Neck Cancer
    Recombinant Keratinocyte Growth Factor For Head &Neck CancerNational Center For Research Resources
    1999 - 2000
  • Phase I/II Study Of Recombinant Keratinocyte Growth Factor In Head/Neck Cancer
    Phase I/II Study Of Recombinant Keratinocyte Growth Factor In Head/Neck CancerNational Center For Research Resources
    1999 - 1999
  • OPEN Label Randomized Study To Eval Effect Safety Of 2 Treatments
    OPEN Label Randomized Study To Eval Effect Safety Of 2 TreatmentsNational Center For Research Resources
    1999 - 2000
  • Phase II Study To Evaluate Safety Of Two Treatment Regimes For Head/Neck Cancer
    Phase II Study To Evaluate Safety Of Two Treatment Regimes For Head/Neck CancerNational Center For Research Resources
    1999 - 1999
  • Temozolomide Treatment In Metastatic Melanoma With Brain Metastases
    Temozolomide Treatment In Metastatic Melanoma With Brain MetastasesNational Center For Research Resources
    1999 - 1999
  • Phase I Study Of Temozolomide In Combo With Cisplatin In Advanced Cancer PTS
    Phase I Study Of Temozolomide In Combo With Cisplatin In Advanced Cancer PTSNational Center For Research Resources
    1998 - 1999
  • Phase I Study Of Recurrent Or Metastatic Squamous Cell Carcinoma Of Head/Neck
    Phase I Study Of Recurrent Or Metastatic Squamous Cell Carcinoma Of Head/NeckNational Center For Research Resources
    1997 - 2002
  • Phase I Study Of Temozolomide In Combination With Cisplatin In Advanced Cancer
    Phase I Study Of Temozolomide In Combination With Cisplatin In Advanced CancerNational Center For Research Resources
    1997 - 1997
  • Phase II Study Of Temozolomide (SCH52365) Prior To Radiation Therapy
    Phase II Study Of Temozolomide (SCH52365) Prior To Radiation TherapyNational Center For Research Resources
    1997 - 2002
  • Phase II Study Of Suramin In Patients With Metastatic Melanoma
    Phase II Study Of Suramin In Patients With Metastatic MelanomaNational Center For Research Resources
    1997 - 2000
  • Phase II Trial Of Topotecan In Patients With Metastatic Squamous Carcinoma
    Phase II Trial Of Topotecan In Patients With Metastatic Squamous CarcinomaNational Center For Research Resources
    1996 - 1997

Dr. Agarwala's Professional Memberships

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • AmeriHealth Direct POS
  • Amerihealth HMO
  • AmeriHealth PPO
  • BCBS Blue Card PPO
  • BCBS Illinois PPO
  • Capital BC Keystone Health Plan Central HMO
  • Capital Blue Cross PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Great West PPO
  • HealthAmerica HealthAssurance PPO
  • Highmark BCBS ClassicBlue
  • Highmark BCBS PPOBlue
  • Humana ChoiceCare Network PPO
  • IBC Keystone HMO / POS
  • IBC Personal Choice PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Alternate Names

  • Dr. Sanjiv Agarwala, Dr. Sanjiv Agarwala, MD, Dr. S Agarwala, Dr. Sanjiv S Agarwala

14 Colleague Invites!
Is this you? If so, register to see 14 messages.

Physicians, view Dr. Agarwala's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV